Gastrointestinal disease

The Europe millets market was valued at US$ 1,327.96 million in 2018 and is expected to grow at a CAGR of 5.4% from 2019 to2027 to reach US$ 2,132.00 million by 2027

Saturday, May 23, 2020 - 2:05am

The Europe millets market was valued at US$ 1,327.96 million in 2018 and is expected to grow at a CAGR of 5.4% from 2019 to2027 to reach US$ 2,132.00 million by 2027.

Key Points: 
  • The Europe millets market was valued at US$ 1,327.96 million in 2018 and is expected to grow at a CAGR of 5.4% from 2019 to2027 to reach US$ 2,132.00 million by 2027.
  • Millets are an ideal food for people suffering from chronic diseases such as diabetes and heart diseases.
  • Regular consumption of millets helps in preventing gastrointestinal problems and other diseases related to kidney and liver.
  • Some of the players present in the Europe millets market are Just Organik, Shimla Hills Offerings Pvt.Ltd, Sresta Natural Bioproducts Pvt.

VBL Presents New Data on MOSPD2 Antibodies as Potential Treatment for NASH and Colitis at DDW

Wednesday, May 6, 2020 - 12:00pm

Treatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model.

Key Points: 
  • Treatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model.
  • VBL's ePoster entitled MOSPD2: A novel therapeutic target for the treatment of inflammatory digestive disorders, was presented at the Digestive Disease Week (DDW) 2020 virtual meeting.
  • VBL's data demonstrate that MOSPD2 plays a role in the pathogenesis of NASH and colitis, by inhibiting the accumulation of monocytes in the affected tissue.
  • Targeting of MOSPD2 using specific monoclonal antibodies, such as the proprietary ones developed by VBL, may offer a novel and distinct treatment for chronic immune-inflammatory indications including colitis and NASH.

Motus GI to Release First Quarter 2020 Results and Provide a Business Update on May 14th

Monday, May 4, 2020 - 11:04pm

A replay of the webcast will be archived on the Motus GI website, www.motusgi.com , for 90 days following the event.

Key Points: 
  • A replay of the webcast will be archived on the Motus GI website, www.motusgi.com , for 90 days following the event.
  • Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
  • The Companys flagship product is the Pure-VuSystem, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.
  • Motus GI believes the Pure-VuSystem may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and enhancing the quality of an exam.

Global Endoscopes Industry Outlook to 2027 by Product, Application, End-use and Region

Friday, May 1, 2020 - 12:15pm

Gastrointestinal (GI) endoscopy emerged as the leading application segment in the global market.

Key Points: 
  • Gastrointestinal (GI) endoscopy emerged as the leading application segment in the global market.
  • Growing geriatric population and rising burden of gastrointestinal diseases are among the key factors responsible for rising demand for GI endoscopy.
  • In addition, disposable endoscopes are increasingly used owing to technological advancements and launch of new products and the risk of infection associated with conventional reusable endoscopes.
  • Preference for these surgeries has led to an increase in development of capsule endoscopes and robot-assisted endoscopes.

AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites

Wednesday, April 29, 2020 - 1:00pm

The TDN is a collaborative network of CF clinical trial specialists supported by the Cystic Fibrosis Foundation (CFF).

Key Points: 
  • The TDN is a collaborative network of CF clinical trial specialists supported by the Cystic Fibrosis Foundation (CFF).
  • We are very pleased to receive the continued support of the Therapeutics Development Network for our Phase 2b OPTION 2 trial, which will allow for full study participation in the TDN sites, said James Pennington, M.D., Chief Medical Officer of AzurRx.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
  • AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a biopharmaceutical company engaged in the development of non-systemic biologics for the treatment of patients with gastrointestinal disorders.

Motus GI Receives CE Mark Approval for GEN2 Pure-Vu System

Friday, March 27, 2020 - 1:12pm

Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced receiving CE (Conformit Europene) Mark approval for the GEN2 Pure-Vu System.

Key Points: 
  • Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced receiving CE (Conformit Europene) Mark approval for the GEN2 Pure-Vu System.
  • The CE Mark signifies that the Pure-Vu System meets the essential requirements of all relevant European Medical Device Directives.
  • Receiving this regulatory clearance allows Motus GI to commercialize the Pure-Vu System and disposable sleeves across the EU and other CE Mark geographies.
  • Motus GI estimates that approximately 1.5 million inpatient procedures take place in the U.S. annually and approximately 4 million procedures take place worldwide each year.

Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Tuesday, March 24, 2020 - 8:01pm

Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.

Key Points: 
  • Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.
  • The Companys lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils.
  • In these studies, antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis.
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Global C-Reactive Protein Testing Market Expected to Grow with a CAGR of 1.3% During the Forecast Period, 2020-2027 - ResearchAndMarkets.com

Friday, March 13, 2020 - 12:10pm

The global C-reactive protein testing market size is expected to reach USD 1.9 billion by 2027, growing at a CAGR of 1.3% during the forecast period.

Key Points: 
  • The global C-reactive protein testing market size is expected to reach USD 1.9 billion by 2027, growing at a CAGR of 1.3% during the forecast period.
  • Several studies have shown the role of C-reactive proteins as an inflammatory marker in gastrointestinal diseases.
  • The initiatives undertaken by government agencies to increase awareness as well as uptake of point-of-care are factors driving the market.
  • The rising prevalence of gastrointestinal diseases coupled with subsequent demand for robust disease testing protocols has driven the market to a considerable extent.

Motus GI to Release Fourth Quarter 2019 Results and Provide a Business Update on March 30th

Wednesday, March 4, 2020 - 1:00pm

A replay of the webcast will be archived on the Motus GI website, www.motusgi.com , for 90 days following the event.

Key Points: 
  • A replay of the webcast will be archived on the Motus GI website, www.motusgi.com , for 90 days following the event.
  • Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
  • The Companys flagship product is the Pure-Vu System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.
  • Motus GI believes the Pure-Vu System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and enhancing the quality of an exam.

IFFGD Shares GI Developments with #GivingTuesday

Monday, December 2, 2019 - 1:38pm

"IFFGD strives to support and provide resources to those affected by gastrointestinal disorders.

Key Points: 
  • "IFFGD strives to support and provide resources to those affected by gastrointestinal disorders.
  • In May 2019, IFFGD launched a video series program, GI Research on the Road.
  • It features IFFGD interviews conducted at medical meetings with GI healthcare experts who highlight research and developments in the GI field, as well as, share valuable insights to raise awareness about research and inform the general and patient community affected by a chronic gastrointestinal disorder.
  • In 2020, IFFGD wants to continue the GI Research on the Road program with a goal of 40 new videos from six medical meetings.